Trial · NCT04950127
Adverse events234
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 234
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Part A: Placebo | 7 | 118 | 8 |
| other | Anaemia | Blood and lymphatic system disorders | Part A: Linerixibat 40 Milligrams (mg) | 2 | 119 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | Part B: Placebo in Part A and Part B | 0 | 53 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Part B: Placebo in Part A and Linerixibat 40 mg in Part B | 0 | 52 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Part B: Linerixibat 40 mg in Part A and Placebo in Part B | 0 | 46 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Part B: Linerixibat 40 mg in Part A and Part B | 0 | 45 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Part A: Placebo | 6 | 118 | 6 |
| other | Abdominal distension | Gastrointestinal disorders | Part A: Linerixibat 40 Milligrams (mg) | 8 | 119 | 10 |
| other | Abdominal distension | Gastrointestinal disorders | Part B: Placebo in Part A and Part B | 0 | 53 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Part B: Placebo in Part A and Linerixibat 40 mg in Part B | 0 | 52 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Part B: Linerixibat 40 mg in Part A and Placebo in Part B | 0 | 46 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Part B: Linerixibat 40 mg in Part A and Part B | 0 | 45 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Part A: Placebo | 4 | 118 | 4 |
| other | Abdominal pain | Gastrointestinal disorders | Part A: Linerixibat 40 Milligrams (mg) | 22 | 119 | 27 |
| other | Abdominal pain | Gastrointestinal disorders | Part B: Placebo in Part A and Part B | 0 | 53 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Part B: Placebo in Part A and Linerixibat 40 mg in Part B | 0 | 52 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Part B: Linerixibat 40 mg in Part A and Placebo in Part B | 0 | 46 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Part B: Linerixibat 40 mg in Part A and Part B | 0 | 45 | 0 |
| other | Abdominal pain upper | Gastrointestinal disorders | Part A: Placebo | 5 | 118 | 6 |
| other | Abdominal pain upper | Gastrointestinal disorders | Part A: Linerixibat 40 Milligrams (mg) | 8 | 119 | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04950127/events